Biotech News
Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
ANN ARBOR, Mich., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Aurobindo Pharma Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against
